Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
NCT00156143
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Males or females : Chronological age > or = 15 years and < or = 20 years for females
- Chronological age > or = 17 years and < or = 20 years for males
- GHD of childhood onset treated for at least 2 years
- Last GH injection at least 12 months before baseline visit
- Turner's syndrome
- Chronic hepatic impairment as shown by GGT and / or ASAT and / or ALAT > 2 X ULN
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Bratislava,
- Bratislava,
- Lubochna,
- Modena,
- Nashville, Tennessee
- Liverpool, Merseyside
- Liverpool, Merseyside
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents | |||
Official Title ICMJE | GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial. | |||
Brief Summary | To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Growth Hormone Deficiency | |||
Intervention ICMJE |
| |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 90 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | April 2005 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 15 Years to 20 Years (Child, Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Not Provided | |||
Removed Location Countries | France | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00156143 | |||
Other Study ID Numbers ICMJE | 307-MET-9002-016 A6281018 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | July 2007 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |